Insights into the treatment of metastatic breast cancer in post-menopausal women: Fulvestrant/Faslodex, a selective estrogen receptor down-regulator, increases the expression of tumor suppressor GRHL3 via down regulation of its target gene, 18/April/2014, 22.28

Insights into the treatment of metastatic breast cancer in post-menopausal women: Fulvestrant/Faslodex, a selective estrogen receptor down-regulator, increases the expression of SOD3 via down regulation of its target gene, 18/April/2014, 22.25
April 18, 2014
Molecular cancer therapy: Radicicol/Monorden, an HSP-90 inhibitor, increases the expression of tumor suppressor p53 homologue TAp63 via down regualtion of its target gene, 18/April/2014, 22.32
April 18, 2014
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Insights into the treatment of metastatic breast cancer in post-menopausal women: Fulvestrant/Faslodex, a selective estrogen receptor down-regulator, increases the expression of tumor suppressor GRHL3 via down regulation of its target gene, 18/April/2014, 22.28, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.